The OncAlert oral cancer risk assessment system from Vigilant Biosciences Inc, Miami, is based on patented technology and designed to detect specific protein markers known to indicate an elevated risk for oral cancer, even before symptoms are observed. Noninvasive and easy to administer, the procedure requires only a simple, oral rinse.
The system includes the OncAlert oral cancer rapid point-of-care risk assessment test and the OncAlert oral cancer CD44 + total protein lab test. The products are not yet commercially available; they are currently undergoing the CE mark registration process and are expected to be released in the spring of 2015.
Making its debut at the International Dental Show on March 10–14, 2015, in Cologne, Germany, the system will be on display at Hall 4.2 Booth #N049. In addition, John Comisi, DDS, MAGD, Vigilant chief dental officer, will present “Improving Early Detection of Oral Cancer with Salivary Diagnostics,” on Thursday, March 12, at 10 a.m., in Speakers’ Corner, Hall 3.1 M010.
“As hundreds of thousands continue to be diagnosed with oral cancer every year, our simple, specific and affordable test can aid in earlier detection of risk and intervention of this disease,” says Matthew H.J. Kim, JD, founder, chairman, and CEO of Vigilant Biosciences. “We are committed to working with dental professionals around the world to incorporate this test seamlessly into their standard practice.”
High-risk populations, such as current and former tobacco users, those who consume alcohol, and people with human papillomavirus (HPV), can especially benefit from the system.